Group 1 - Merck & Co., Inc. held its Q3 2024 earnings call on October 31, 2024, with key participants including the CEO, CFO, and President of Merck Research Labs [1][3]. - The call included discussions on GAAP results, which accounted for acquisition-related charges and restructuring costs, and highlighted the distinction between GAAP and non-GAAP results [4].

| --- | --- | --- | --- | |------------------------------------------|-------|-------|-------| | | | | | | | | | | | Merck Q3 2024 Earnings October 31, 2024 | | | | | | | | | Agenda 2 | --- | --- | --- | --- | --- | |-------------------------------|-----------------------------------------|-----------------------|---------|-------------------| | | | | | | | | | | | | | | | | | | | | | | | | | Strategy and Business Update | Business/Financial Results and Outlook | Research Update | Session | Question & Answe ...

Merck (MRK) reported third-quarter 2024 adjusted earnings of $1.57 per share, which beat the Zacks Consensus Estimate of $1.50. Earnings declined 26% year over year on a reported basis and 23% excluding foreign exchange (Fx) impact due to one-time charges incurred by the company related to business development.Revenues rose 4% year over year (7% excluding Fx) to $16.66 billion. Sales also beat the Zacks Consensus Estimate of $16.55 billion.All sales growth numbers discussed below are on a year-over-year bas ...

For the quarter ended September 2024, Merck (MRK) reported revenue of $16.66 billion, up 4.4% over the same period last year. EPS came in at $1.57, compared to $2.13 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $16.55 billion, representing a surprise of +0.65%. The company delivered an EPS surprise of +4.67%, with the consensus EPS estimate being $1.50.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Merck (MRK) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.50 per share. This compares to earnings of $2.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.67%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $2.16 per share when it actually produced earnings of $2.28, delivering a surprise of 5.56%.Over the last four quarters, the compan ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

Exhibit 99.2 MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1a 2024 2023 % Change | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------|---------------------|----------------------|----------------|---------------------|------------------|-------------------|-------------------------------|-------------------------------|----------------------|-- ...

The exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on Feb. 5, 2024.Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business. But Merck's vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales. Revenue from the sh ...

Core Viewpoint - Merck (MRK) is expected to report a quarterly earnings decline of 29.6% year over year, with earnings per share (EPS) projected at $1.50, while revenues are forecasted to increase by 3.7% to $16.54 billion [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 2.1% over the past 30 days, indicating a reassessment by analysts [1][2]. - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [2]. Key Metrics Forecast - Analysts predict 'Sales- Oncology- Alliance Revenue- Lynparza' at $346.03 million, reflecting a year-over-year increase of 15.7% [4]. - 'Sales- Oncology- Keytruda' is expected to reach $7.38 billion, indicating a 16.5% increase from the previous year [4]. - 'Sales- Hospital Acute Care- Zerbaxa' is forecasted at $59.30 million, showing an 11.9% year-over-year change [4]. Additional Sales Projections - 'Sales- Oncology- Alliance revenue- Lenvima' is estimated at $275.08 million, with a year-over-year change of 5.8% [5]. - 'Sales- Hospital Acute Care- Bridion - U.S.' is projected to be $309.22 million, reflecting a 16.7% increase year over year [5]. - 'Sales- Oncology- Keytruda - International' is expected to be $2.93 billion, indicating a 15.2% increase [6]. Regional Sales Insights - 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' is projected at $168.05 million, with a 9.8% year-over-year change [7]. - 'Sales- Oncology- Alliance revenue- Lynparza - International' is expected to reach $177.98 million, reflecting a 21.9% increase [7]. - 'Sales- Oncology- Alliance revenue- Lenvima - U.S.' is forecasted at $180.66 million, indicating a 12.9% increase [8]. - 'Sales- Hospital Acute Care- Zerbaxa - U.S.' is expected to be $32.48 million, reflecting a 12% increase year over year [9]. Stock Performance - Merck shares have decreased by 8.5% over the past month, contrasting with the Zacks S&P 500 composite's increase of 2% [9].

There's a lot to like here.No matter how well the stock market is performing, investors can always find some companies that aren't keeping pace with broader equities. This year, pharmaceutical giant Merck (MRK -1.79%) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%.Even when we zoom out, Merck hasn't performed particularly well in recent years. The company has significantly trailed the S&P 500 over the past decade. Does that mean investors should stay away from Me ...